IOVA — Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 838
- Website: https://www.iovance.com
Latest SEC filings for IOVA
- 3 — 2026-10-02
- 8-K — 2026-09-29
- SCHEDULE 13G — 2026-08-07
- 8-K — 2026-08-06
- 10-Q — 2026-08-06
- 8-K — 2026-08-06
- 8-K — 2026-07-02
- S-3ASR — 2026-06-18
- S-8 — 2026-06-18
- S-8 — 2026-06-18
Latest IOVA news
- — Iovance sees long-term response for Amtagvi in first-line melanoma (seekingalpha_market)
- — These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks Investment Research)
- — How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks Investment Research)
- — 55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP
- — Iovance: Buy Now Before Many Growth Catalysts Kick In (seekingalpha.com)
- — These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks Investment Research)
- — These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- — Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire Inc.)
- — IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 (Zacks Investment Research)
- — IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 (zacks.com)
Educational tool only — not investment advice.